01 Use of Biologics as a First-Line Therapy The market is witnessing a major shift toward the adoption of biologics as the preferred first-line therapy. Historically, patients relied primarily on corticosteroids and immunosuppressants, which often provided limited long-term control and were associated with safety concerns. Today, the increasing number of biologic approvals is transforming disease management and expanding therapeutic access. The U.S. Food and Drug Administration recently approved two novel biologic medications, including Nemluvio, for the treatment of moderate to severe atopic dermatitis.Therefore, these advancements signify a shift toward targeted biologic therapies, enhancing efficacy, safety, and establishing a new standard in atopic dermatitis.
02 Non-Steroidal Topical Drugs are a Major Trend Reshaping the Treatment Options The growing approvals of topical therapies alongside biologic drugs represent a key market trend, driving advancements in treatment options. For example, in July 2024, the U.S. FDA approved Roflumilast 0.15% cream developed by Arcutis Biotherapeutics for adults and children aged 6 years and older. This non-steroidal cream provided a safer alternative to steroid cream.Thus, by expanding non-steroidal treatment, Arcutis assisted patients and doctors in managing atopic dermatitis more safely and effectively.
March 2026 Sanofi expanded its dermatology portfolio with continued advancements in Dupixent® (dupilumab) and immune-mediated disease therapies, supporting treatment options for moderate-to-severe atopic dermatitis.
January 2026 Eli Lilly expanded its immunology portfolio with advancements in dermatology therapies, including treatments targeting inflammatory pathways involved in atopic dermatitis and other skin disorders.
October 2025 AbbVie expanded its dermatology portfolio with continued development of immune-modulating therapies designed for chronic inflammatory skin conditions, including atopic dermatitis.
August 2025 Incyte expanded its dermatology product portfolio with innovative topical and systemic therapies designed to support patients with inflammatory skin diseases, including atopic dermatitis.